FDA approves expanded indication for FoundationOneCDx as a companion diagnostic for Lynparza

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved FoundationOneCDx to be used as a companion diagnostic for Lynparza (Olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login